Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites.
Inhibitors of sterol and phospholipid biosynthesis in kinetoplastid parasites such as Trypanosoma cruzi, the causative agent of Chagas' disease, and different species of Leishmania have potent and selective activity as chemotherapeutic agents in vitro and in vivo. Recent work with the sterol C14 alpha-demethylase inhibitor D0870, a bis triazole derivative, showed that this compound is capable of inducing radical parasitological cure in murine models of both acute and chronic Chagas' disease. Other inhibitors of this type, such as SCH 56592, have also shown curative, rather than suppressive, activity against T. cruzi in these models. Leishmania species have different susceptibilities to sterol biosynthesis inhibitors, both in vitro and in vivo. Leishmania braziliensis promastigotes, naturally resistant to C14 alpha-demethylase inhibitors such as ketoconazole and D0870, were susceptible to these drugs when used in combination with the squalene epoxidase inhibitor terbinafine. Inhibitors of delta 24(25) sterol methyl transferase have been shown to act as potent antiproliferative agents against Trypanosoma cruzi, both in vitro and in vivo. New inhibitors of this type which show enhanced activity and novel mechanisms of action have been synthesized. Recent work has also demonstrated that this type of enzyme inhibitors can block sterol biosynthesis and cell proliferation in Pneumocystis carinii, a fungal pathogen which had previously been found resistant to other sterol biosynthesis inhibitors. Ajoene, an antiplatelet compound derived from garlic, was shown to have potent antiproliferative activity against epimastigotes and amastigotes of Trypanosoma cruzi in vitro; this activity was associated with a significant alteration of the phospholipid composition of the cells with no significant effects on the sterol content. In addition, alkyllsophospholipids such as ilmofosine, miltefosine and edelfosine have been shown to block the proliferation of T. cruzi and Leishmania and alter both the phospholipid and sterol composition. These results indicate the potential of lipid biosynthesis inhibitors as useful therapeutic agents in the treatment of leishmaniasis and Chagas' disease.
Urbina
J A
JA
Laboratorio de Quimica Biologica, Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela.
D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology*; D065607:Cytochrome P-450 Enzyme Inhibitors; D015195:Drug Design; D016830:Kinetoplastida / Q000187:drug effects*; D008055:Lipids / Q000096:biosynthesis*; D008780:Methyltransferases / Q000037:antagonists & inhibitors; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D010271:Parasites / Q000187:drug effects; D010743:Phospholipids / Q000096:biosynthesis; D058886:Sterol 14-Demethylase; D013261:Sterols / Q000096:biosynthesis; D014230:Triazoles / Q000494:pharmacology
D000981:Antiprotozoal Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D008055:Lipids; D010743:Phospholipids; D013261:Sterols; D014230:Triazoles; C058219:ICI 195739; D010088:Oxidoreductases; D058886:Sterol 14-Demethylase; D008780:Methyltransferases; C022670:delta 24-sterol methyltransferase